What AMP® ALS Partners Are Saying

ALS Association

“It will take all of us working together to make ALS a livable disease and ultimately find a cure. That is why we are pleased to join with other non-profits, as well as public and private organizations, to support AMP ALS. By building on our collective expertise and insight, this partnership will continue to advance the discovery and development of new treatments and biomarkers, accelerating our fight against this devastating disease.”

Kuldip Dave, PhD
Senior Vice President, Research
ALS Association


ALS United

“ALS United is honored to champion the AMP ALS project, made possible by the steadfast support of our members nationwide. This initiative underscores the significance of collaboration between public and private organizations in advancing ALS research. With its comprehensive strategy, including a central ALS Knowledge Platform and the pursuit of validated biomarkers and therapeutic targets, this project holds immense promise in addressing the urgent needs of people living with ALS. Together, we’re not just envisioning hope and progress; we’re actively forging the path towards a brighter future for the people we exist to serve.”

Jerry Dawson
Executive Director
ALS United


The Association for Frontotemporal Degeneration

“Many of the families supported by AFTD know all too well that FTD and ALS can exist on a spectrum. While clinical care and research are often siloed, the two diseases can co-occur in people with sporadic disease and in people with genetic variants. People with C9orf72 repeat expansions are at risk of developing FTD, ALS, or a combination of the two. AFTD is honored and grateful to join this ALS initiative, to do our part to help accelerate research at the intersection of these two conditions and to ensure that the needs of all affected families are recognized and addressed.”

Penny Dacks, PhD
Senior Director of Scientific Initiatives
AFTD


Biogen

“Over the past decade, Biogen has been committed to understanding and addressing the underlying pathophysiology of ALS. We are honored to join the Foundation for the National Institutes of Health and other partners to accelerate these efforts. As co-chair of AMP ALS, I have seen firsthand the value of the collective expertise and shared determination of all involved in this initiative. While we have a number of rich datasets that have been generated over the years, they are decentralized and, in some cases, incomplete. Through the work of AMP ALS, I am confident we will identify new targets and tools to support diagnosis, prognostication, and assessment of treatment response more efficiently – expediting ALS drug development as a whole.”

Stephanie Fradette, PharmD
Head of Neuromuscular Development Unit
Biogen


EMD Serono

“Driving meaningful progress in therapeutic development in ALS requires collaboration, and we are pleased to support the AMP ALS initiative. By working together, we will bring together the necessary experts to find solutions that will help to understand diverse disease drivers, accelerate ALS drug discovery & development and ultimately, make impactful differences for people living with ALS.”

Amy Kao, MD, MPH, MS
Senior Vice President & Global Head of Research Unit – Neuroscience & Immunology
EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany)


GSK

“ALS is a devastating neurodegenerative disease with few efficacious treatments available. There is an urgent need to understand the disease at a molecular level, to identify novel molecular targets for therapeutic intervention, to identify novel biomarkers for diagnostic, disease progression, and therapeutic response and to address patient heterogeneity. All of these are integral components of the new AMP-ALS and GSK is excited to partner with FNIH in this public-private highly collaborative endeavor to accelerate discovery and development of medicines for patients and to get ahead of the disease together.”

Sanjay Kumar, PhD
VP and Head, Emerging Specialties Biology Unit
GSK


Mitsubishi Tanabe Pharma America

“Amyotrophic lateral sclerosis (ALS) is one of the most devastating health problems due to relentless loss of multiple functions. The impact is felt not only by the patient, but also by the family and beyond. As result of loss of independence in personal activities, and ultimately respiratory failure, patients and families have been confronted with many daily difficulties. Despite different efforts to reframe the management of ALS, controlling the disease has shown to be very challenging. It also has a tremendous economic, psychological, and social impact. We are proud to be a member of an esteemed group to advance knowledge of this illness that could help lead to solutions and offer relief to people with ALS.”

Bijan Nejadnik, MD
Chief Medical Officer
Global Head of Development and Regulatory Affairs
Mitsubishi Tanabe Pharma America, Inc.


QurAlis

“QurAlis is excited to participate in the AMP ALS program to accelerate development of much-needed precision therapeutics and biomarkers which could speed up clinical development timelines as well as aid in more rapid diagnosis and treatment of people with ALS.”

Kasper Roet, PhD
CEO and Founder
QurAlis


ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services

Leave a comment

Your email address will not be published. Required fields are marked *